ICAM1 and breast cancer: Comparable levels of ICAM-1 were also found in patients after BC treatment and in the group of CBI (mean difference: −21.28, 95% CI −111.03 to 68.48, p = 0.92) and comparable levels of anti-NR-2 antibodies in these groups (mean difference: −0.07, 95% CI −0.27 to 0.12, p = 0.75).